What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are considered the standard of care for type 2 diabetes in many countries worldwide. These molecules have profound anti-hyperglycaemic actions with a favourable safety profile. They are now being considered for their robust cardiovascular (CV) pr...
Main Authors: | Jared Berndt, Soo Liang Ooi, Sok Cheon Pak |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/26/16/4822 |
Similar Items
-
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01) -
Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
by: Cristina Bouzas, et al.
Published: (2023-05-01) -
Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01) -
The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients
by: Huang CF, et al.
Published: (2023-01-01) -
Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)